SNDX Stock News & Catalysts – Syndax Pharmaceuticals

FEATURED

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

New

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the

Summary

Nov 9, 2026, 5:26 PM ·Globe Newswire

RECENT

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 4, 2026, the

Nov 4, 2026, 4:01 PM ·Globe Newswire

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

Nov 4, 2026, 9:01 AM ·Globe Newswire

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax’s scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia

Nov 4, 2026, 9:00 AM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ:SNDX). Such investors are

Nov 3, 2026, 5:50 PM ·Globe Newswire

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute

Nov 2, 2026, 4:01 PM ·Globe Newswire

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage

Nov 2, 2026, 4:01 PM ·Globe Newswire

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) --

Oct 30, 2026, 9:01 AM ·Globe Newswire

Syndax Announces Participation in November Investor Conferences

NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief

Oct 30, 2026, 7:00 AM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (NASDAQ:SNDX). Such investors are advised

Oct 29, 2026, 10:00 AM ·PRNewswire

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third

Oct 26, 2026, 7:00 AM ·Globe Newswire

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. ("Syndax" or

Oct 17, 2026, 9:22 PM ·Business Wire

Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the

Oct 15, 2026, 4:01 PM ·Globe Newswire

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending

Oct 13, 2026, 10:17 PM ·PRNewswire

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues

Oct 12, 2026, 4:01 PM ·Globe Newswire

Syndax Pharmaceuticals, Inc. SNDX · News